ADCTN
Australian Diabetes Clinical Trials Network
Now Reviewing Protocols: Investigator-Initiated Trials
ADCTN clinical trial support is now open for submissions
We’re excited to share that the Australian Diabetes Clinical Trials Network (ADCTN) is now accepting protocol submissions for review and endorsement for investigator-initiated trials.
Led in partnership by Diabetes Australia and the Australian Centre for Accelerating Diabetes Innovations (ACADI), ADCTN supports investigator-initiated clinical trials by offering free, structured feedback from leading diabetes researchers and people with lived experience.
ADCTN offers two tailored review pathways:
- Expert Review & Feedback – ideal for protocol refinement ahead of ethics or funding submission
- Formal Endorsement – including presentation to the ADCTN Executive Committee and a Letter of Endorsement if approved
Please read the guidelines for details on processes including key dates.
Ready to submit your protocol for review? Ensure you have carefully read the guidelines and submit your protocol together with the completed checklist to ADCTN-info@unimelb.edu.au before the submission deadline (see guidelines for dates).
For more information, or if you have any questions, feel free to reach out to us at ADCTN-info@unimelb.edu.au.
** Please note - ADCTN is currently not accepting Industry trial protocols for review. This is expected to start in late 2026, with an associated fee.
Launch of the ADCTN
Image: (L-R) Keren Pointon, Dr Lisa Hayes, Dr Anish Menon, Prof Elif Ekinci, Justine Cain, Susan Kozij, Prof David O’Neal, Prof Josephine Forbes, Prof Grant Brinkworth, Andrew Bowskill
The ADCTN was launched on September 3, 2024 in Brisbane.
A groundbreaking new collaboration in diabetes research announced in Brisbane will improve outcomes for people living with diabetes.
ACADI and Diabetes Australia have joined forces to announce the Australian Diabetes Clinical Trials Network (ADCTN), a research initiative designed to increase the number of diabetes clinical trials in Australia.
Diabetes Australia Group CEO Justine Cain said clinical trials are a cornerstone of medical research and innovation because of their real-world application.
“People living with diabetes are at the heart of everything we do,” Ms Cain said.
“Clinical trials ensure that new treatments deliver real benefits to people, while also identifying any potential risks or side effects.
“Our new network will increase the number of diabetes clinical trials being funded and conducted in Australia. This will make a huge difference in the lives of people living with diabetes because it means new and innovative treatments and interventions can be tested and hopefully become available.”
ACADI director and head of Medicine at Melbourne University, Professor Elif Ekinci, said the network will support diabetes researchers by providing expert review and feedback of clinical trial protocols and grant funding applications.
“Clinical trials are essential to inform new ways to prevent, detect, or treat diabetes,” Professor Ekinci said.
“By advancing our understanding of how different treatments work and evaluating their impact, clinical trials play a crucial role in improving the care of people living with diabetes. Their results contribute to the development of more effective, safer healthcare options and help inform evidence-based practices in medicine.”